{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T18:08:53Z","timestamp":1781806133686,"version":"3.54.5"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,29]]},"abstract":"<jats:p>Optimal medical therapy, including Beta-blockers (BB), inhibitors of the renin-angiotensin system (RAS), and statins, is recommended for patients with acute myocardial infarction (AMI) in the absence of contraindications. However, the optimal duration of these medications has not been clearly established in clinical studies. This observational study aimed to investigate the period during which these medications are associated with improved clinical outcomes. Among patients enrolled in the Korea Acute Myocardial Infarction Registry-National Institute of Health (KAMIR-NIH), in-hospital survivors were selected. In a Cox-proportional hazard analysis of 12,200 patients, BB (hazard ratio [HR]\u2005=\u20050.73; 95% confidence interval [CI]\u2005=\u20050.57\u20130.95; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.019), RAS inhibitors (HR 0.70; 95% CI\u2005=\u20050.55\u20130.89; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.004), and statins at discharge (HR\u2005=\u20050.65; 95% CI\u2005=\u20050.48\u20130.87; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.004) were all associated with lower 1-year cardiac mortality. At 1-year, 10,613 patients without all-cause death, myocardial infarction, revascularization, or re-hospitalization due to heart failure were selected for further analysis. RAS inhibitors (HR\u2005=\u20050.53; 95% CI\u2005=\u20050.37\u20130.76; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.001) and statins (HR\u2005=\u20050.30; 95% CI\u2005=\u20050.14\u20130.61; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.001) prescribed at 1-year were associated with lower 2-year cardiac mortality, whereas BB were not (HR\u2005=\u20050.79; 95% CI\u2005=\u20050.51\u20131.23; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.23). However, none of these medications prescribed at 2-years were associated with reduced 3-year cardiac mortality among the 9232 patients who remained event-free until then. RAS inhibitors and statins were associated with reduced cardiac mortality for up to 2-years, and BB for up to 1-year after the initial attack. The effectiveness of these medications beyond these periods remains questionable.<\/jats:p>","DOI":"10.1097\/md.0000000000040697","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T21:01:06Z","timestamp":1732914066000},"page":"e40697","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Optimal duration of medical therapy for patients with acute myocardial infarction"],"prefix":"10.1097","volume":"103","author":[{"given":"Ki Yung","family":"Boo","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Jeju National University College of Medicine, Jeju, Republic of Korea"},{"name":"Department of Internal Medicine, Jeju National University Hospital, Jeju, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4322-0703","authenticated-orcid":false,"given":"Seung-Jae","family":"Joo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jeju National University College of Medicine, Jeju, Republic of Korea"},{"name":"Department of Internal Medicine, Jeju National University Hospital, Jeju, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Geun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jeju National University College of Medicine, Jeju, Republic of Korea"},{"name":"Department of Internal Medicine, Jeju National University Hospital, Jeju, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon-Hyouk","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jeju National University College of Medicine, Jeju, Republic of Korea"},{"name":"Department of Internal Medicine, Jeju National University Hospital, Jeju, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Yi","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jeju National University College of Medicine, Jeju, Republic of Korea"},{"name":"Department of Internal Medicine, Jeju National University Hospital, Jeju, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geum","family":"Ko","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jeju National University Hospital, Jeju, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Eun","family":"Yun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jeju National University Hospital, Jeju, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung Ho","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the KAMIR-NIH investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"e2022057","DOI":"10.4178\/epih.e2022057","article-title":"Epidemiology of myocardial infarction in Korea: hospitalization incidence, prevalence, and mortality.","volume":"44","author":"Kim","year":"2022","journal-title":"Epidemiol Health"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines.","volume":"127","author":"O\u2019Gara","year":"2013","journal-title":"Circulation"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes.","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2012.07.013","article-title":"2012 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.","volume":"60","author":"Fihn","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines.","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1093\/eurheartj\/ehy407","article-title":"Association is not causation: treatment effects cannot be estimated from observational data in heart failure.","volume":"39","author":"Rush","year":"2018","journal-title":"Eur Heart J"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1253\/circj.CJ-16-0061","article-title":"Multicenter cohort study of acute myocardial infarction in Korea-Interim Analysis of the Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry.","volume":"80","author":"Kim","year":"2016","journal-title":"Circ J"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","article-title":"Third universal definition of myocardial infarction.","volume":"126","author":"Thygesen","year":"2012","journal-title":"Circulation"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4266\/acc.2023.00955","article-title":"Beta-blocker therapy in patients with acute myocardial infarction: not all patients need it.","volume":"38","author":"Joo","year":"2023","journal-title":"Acute Crit Care"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.amjmed.2014.05.032","article-title":"Clinical outcomes with \u03b2-blockers for myocardial infarction: a meta-analysis of randomized trials.","volume":"127","author":"Bangalore","year":"2014","journal-title":"Am J Med"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1093\/eurheartj\/ehaa376","article-title":"Long-term \u03b2-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study.","volume":"41","author":"Kim","year":"2020","journal-title":"Eur Heart J"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/eurheartj\/ehaa1058","article-title":"Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study.","volume":"42","author":"Holt","year":"2021","journal-title":"Eur Heart J"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"e019017","DOI":"10.1161\/JAHA.120.019017","article-title":"One-year landmark analysis of the effect of beta-blocker dose on survival after acute myocardial infarction.","volume":"10","author":"Goldberger","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMoa2401479","article-title":"Beta-blockers after myocardial infarction and preserved ejection fraction.","volume":"390","author":"Yndigegn","year":"2024","journal-title":"N Engl J Med"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group.","volume":"333","author":"K\u00f8ber","year":"1995","journal-title":"N Engl J Med"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events.","volume":"358","author":"Yusuf","year":"2008","journal-title":"N Engl J Med"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease.","volume":"351","author":"Braunwald","year":"2004","journal-title":"N Engl J Med"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes.","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jacc.2015.07.047","article-title":"Effect of beta-blocker dose on survival after acute myocardial infarction.","volume":"66","author":"Goldberger","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1001\/jama.2012.14785","article-title":"Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction.","volume":"308","author":"Lund","year":"2012","journal-title":"JAMA"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ehjcvp\/pvac064","article-title":"Initial statin dose after myocardial infarction and long-term cardiovascular outcomes.","volume":"9","author":"Kyt\u00f6","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:02:18Z","timestamp":1746316938000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":30,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040697","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}